Curative effect of harringtonine semisynthetic harringtonine and HOAP on nonlymphocytic leukemias. Analysis of 304 cases.
D000328:Adult; D000470:Alkaloids / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001752:Blast Crisis / Q000188:drug therapy; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D006248:Harringtonines / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000473:pathology; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D000470:Alkaloids; D006248:Harringtonines; D003561:Cytarabine; D014750:Vincristine; D011241:Prednisone